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Summary
 
The requirements for CD8 T cells to provide protection against a localized virus infection in
models of adoptive immunotherapy are not well defined. Here we investigated the protective
value of defined in vitro
 
–
 
generated hemagglutinin (HA) peptide-specific primary CD8 T cell
effectors from the clone 4 T cell receptor transgenic mice, secreting type 1 or type 2 cytokines,
against pulmonary infection with whole influenza virus. Cytotoxic T lymphocytes producing
type 1 and type 2 cytokine (Tc1 and Tc2) populations were equally cytolytic, but Tc1 effectors
and not Tc2 effectors reduced the pulmonary virus titer early during infection. Host recovery
mediated by Tc1 effectors was found to be independent of interferon 
 
g
 
 production. Tc2 effec-
tors entered the lung with delayed kinetics as compared with Tc1 effectors, and after lung entry
Tc2 effector cells did not localize near the infected airway epithelium as did Tc1 effectors but
were found within clusters of inflammatory cells distant from the epithelium. We also show
that the expression of several chemokine receptors was selectively regulated in the Tc1 and Tc2
subsets. Thus, the protective value of a CD8 cell population against pulmonary influenza virus
infection is strongly correlated with its ability to exert its effector potential at the site of virus
infection.
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A
 
variety of factors are involved in the host defense
against virus and in the recovery from pulmonary viral
infections (1, 2). CD8 T cells have been shown to be im-
portant effector cells during pulmonary influenza virus in-
fection, promoting host recovery and virus clearance. The
adoptive transfer of influenza virus–immune cytotoxic T
cells (3) or CD8 T cell clones (4) into lethally influenza-
infected hosts resulted in a reduction of the pulmonary
virus titer and prevention of death. The main effector
mechanism of CD8 T cell populations against influenza
was shown to be contact–dependent lysis (5). Additional
requirements for a CD8 T cell population to be protective
against influenza virus infection have not yet been defined.
CD8 T cells, which were initially described as cytolytic
 
effector cells producing high levels of IFN-
 
g
 
, have only
recently been shown to be a source of a wider variety of
cytokines, including both type 1 and type 2 cytokines (6,
7). Depending on the cytokines present during primary
stimulation, CD8 T cells can be polarized into type 1 and
type 2 CD8 T cells producing IFN-
 
g
 
 and IL-2 or IL-4, IL-5,
IL-6, and IL-10, respectively (8–10). In most of the studies,
including our own, both the Tc1 (CTLs producing type 1
cytokines)
 
1
 
 and Tc2 subsets were shown to be cytolytic (9–
11). Furthermore, we have demonstrated previously that
Tc1 or Tc2 effectors can give rise to Tc1 or Tc2 memory
cells, respectively, indicating that the type 1– and type
2–producing phenotypes are stable (10). There is substantial
evidence that CD8 T cells secreting type 1 and type 2 cy-
tokines also exist in vivo during infection with a number of
pathogens, including influenza virus. IL-5–secreting CD8
T cells have been isolated from lesions from patients with
lepromatous leprosy (12) and from HIV–infected individu-
als with a Job’s-like syndrome (13). Lymphocytic chori-
omeningitis virus–specific CD8 T cells secreting IL-5 have
been shown to be associated with airway eosinophilia (14)
and IL-5– or IFN-
 
g
 
–producing CD8 T cells were found in
murine gut-associated tissues (15). During pulmonary in-
fluenza virus infection, both CD4 and CD8 populations
 
1
 
Abbreviations used in this paper:
 
 HA, hemagglutinin; LT-
 
b
 
, lymphotoxin-
 
b
 
;
MDCK cells, Madine Derby canine kidney cells; t
 
0
 
, before restimulation;
TBLN, tracheal bronchial lymph node; Tc1/Tc2, CTLs producing type
1/type 2 cytokines. 
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isolated from the mediastinal lymph nodes concurrently
produced IL-2, IFN-
 
g
 
, and IL-10 as assessed by Elispot as-
say (16). In addition, both CD4 and CD8 T cells isolated
from the respiratory tract contributed to the mRNA ex-
pression of the cytokines IFN-
 
g
 
, IL-5, and IL-10 (17) and
splenic CD4 and CD8 T cells from influenza-immune
mice were found to produce IL-2, IL-4, and IFN-
 
g
 
 in
vitro
 
 
 
(18).
The observation that CD8 T cells can be a source of sev-
eral cytokines suggests that they may carry out previously
unrecognized in vivo functions in the regulation of im-
mune responses. However, the relative protective value of
CD8 T cell effectors producing different patterns of cyto-
kines against pulmonary virus infection has not yet been
addressed. The patterns of cytokines produced by CD8
Tc1 and Tc2 effectors might recruit cell populations with
distinct effector functions to the site of infection. In addi-
tion, recent evidence suggests that the protective value of T
cell populations might also strongly depend on their ability
to migrate efficiently to infected tissue sites where they
perform their effector function (19). For CD4 T cells, it
was shown that not only the expression of adhesion mole-
cules (20) but also the expression of chemokine receptors
(21, 22) differed profoundly within human Th1 and Th2
clones, suggesting distinct migration patterns of CD4 sub-
sets. Chemokine receptor expression on polarized CD8 T
cell subsets and their migration patterns has not yet been
investigated.
In this paper, we have studied the in vivo function, mi-
gration pattern, and chemokine receptor expression of po-
larized type 1 or type 2 CD8 T cells during pulmonary
influenza virus infection. Primary hemagglutinin (HA)
peptide-specific Tc1 and Tc2 effector cells from clone 4
TCR transgenic mice specific for a nonapeptide from the
transmembrane region of the HA2 molecule from influ-
enza virus were generated in vitro and adoptively trans-
ferred into hosts infected intranasally with 10 LD
 
50 
 
influ-
enza virus (A/PR/8/34).
We show that Tc1 effectors were more effective in pro-
moting virus clearance and host recovery than Tc2 effec-
tors, despite the fact that both populations were equally cy-
tolytic. Delayed entry or accumulation of Tc2 effectors
into the lung and distinct localization of Tc2 effectors
within clusters of inflammatory cells distant from the in-
fected airway epithelium correlated with their ineffective-
ness to clear virus early during infection. In contrast, Tc1
cells entered or accumulated in the lung early and migrated
to the infected airway epithelium. Tc1 and Tc2 effectors
exhibited striking differences in chemokine receptor ex-
pression. These data suggest that the localization of cy-
tolytic effectors together with their cytokine production
are likely to make a major contribution to the effectiveness
of CD8 T cell populations against localized virus infections.
 
Materials and Methods
 
Mice.
 
Mice were purchased from the Animal Breeding Facil-
ity at the Trudeau Institute. Clone 4 V
 
b
 
8.2/V
 
a
 
10 TCR trans-
 
genic mice (23) were provided by Dr. Linda Sherman (The
Scripps Research Institute, La Jolla, CA). The clone 4 TCR
transgenic mice bear the 
 
a
 
 and 
 
b
 
 chains of the clone 4 CTL
specific for the transmembrane peptide, residues 518–528
(IYSTVASSL) of HA2 on H-2K
 
d
 
. The clone 4 TCR transgenic
mice were back-crossed for eight generations with BALB/c
mice. They were also crossed to the IFN-
 
g
 
2/2
 
 background on
BALB/c. The IFN-
 
g
 
2/2
 
 mice were originally purchased from
The Jackson Laboratory (Bar Harbor, ME). BALB/c Thy 1.1
mice were a gift from Dr. Jon Sprent (The Scripps Research In-
stitute, La Jolla, CA).
 
Preparation of Tc1 and Tc2 Effector Cells.
 
CD8 T cells from the
spleens and lymph nodes of clone 4 TCR transgenic mice were
enriched by passing through nylon wool and treating with anti-
CD4 (RL172.4) and anti–heat stable antigen (J11D), and anti–
class II MHC (D3.137, M5114, CA4) mAbs, and complement.
Small resting CD8 T cells were harvested from the bottom inter-
face of a four-layer Percoll gradient (Sigma Chemical Co.). The
freshly isolated T cell populations were 90–95% CD8
 
1
 
V
 
b
 
8
 
1
 
 T
cells. T cell–depleted splenocytes were prepared using anti-
Thy1.2 (HO13.14 and F7D5), anti-CD4 (RL172.4), and anti-
CD8 (3.155) mAbs, and complement, and stimulated with LPS
(25 
 
m
 
g/ml) and Dextran sulfate (25 
 
m
 
g/ml) for 48 h. “APC
blasts” were loaded with the HA peptide (11 
 
m
 
M) at 37
 
8
 
C for 30
min, treated with mitomycin C (50 
 
m
 
g/ml; Sigma Chemical Co.)
at 37
 
8
 
C for 40 min, and washed three times before use. CD8 T
cells were cultured in RPMI 1640 (Irvine Scientific Co.) supple-
mented with penicillin, streptomycin, glutamine (PSG), 2-ME,
Hepes, and 10% FCS (Hyclone Labs.). For effector generation
CD8 T cells from the clone 4 transgenic mice (2 
 
3 
 
10
 
5
 
 cells/ml)
were stimulated with HA peptide–loaded APCs (2 
 
3
 
 10
 
5
 
 cells/ml)
in the presence of IL-2 (20 U/ml, supernatant from the
X63Ag.IL-2 murine cell line), IL-12 (9.2 U/ml, provided by Dr.
Stanley Wolf, Genetics Institute, Inc., Cambridge, MA), and
anti–IL-4 mAb (10 
 
m
 
g/ml, 11B11) for Tc1 cultures and in the
presence of IL-2 (20 U/ml), IL-4 (200 U/ml, X63.Ag.IL-4 su-
pernatant), and anti-IFN-
 
g
 
 mAb (XMG1.2, 20 
 
m
 
g/ml) for Tc2
cultures. On day 4 of culture, effectors were 99% CD8
 
1
 
V
 
b
 
8
 
1
 
.
 
Virus Infections and Cell Transfers.
 
The influenza virus prepa-
ration (A/PR/8/34) grown in the allantoic cavity of 10-d-old
embryonated hen eggs was a gift of Drs. David Morgan and
Linda Sherman (The Scripps Research Institute, La Jolla, CA).
Each mouse was inoculated with a 10 LD
 
50
 
 dose of virus (corre-
sponding to a 10
 
2
 
3
 
 dilution of stock virus in 100 
 
m
 
l PBS) intrana-
sally during light halothane (Halocarbon) anesthesia. Before
adoptive transfer, Tc1 and Tc2 effector cells were washed twice
in HBSS and, if not indicated otherwise, 10
 
7
 
 effector cells were
injected in 0.5 ml PBS via the tail vein within 
 
z
 
1 h after intrana-
sal virus infection.
 
Analysis of Cytokine Production.
 
Enriched CD8 T cells (2 
 
3
 
10
 
5
 
 cells/ml) were stimulated with mitomycin-treated P815 cells
(1.2 
 
3
 
 10
 
6
 
/ml) loaded or not with the HA peptide. IFN-
 
g
 
, IL-4,
and IL-5 were measured by specific ELISAs as previously de-
scribed (10).
 
Cytotoxicity Assay.
 
P815 cells were used as targets and loaded
or not with the indicated concentrations of the HA peptide for
30 min at 37
 
8
 
C. Subsequently, target cells (10
 
6
 
 cells/400 
 
m
 
l
RPMI medium containing 1% FCS) were incubated with 3.7
mBq 
 
51
 
Cr (specific activity 1.85 TBq/g; NEN™
 
 
 
Life Science
Products) for 1 h at 37
 
8
 
C. Labeled targets were washed three
times before use. CD8 T cells were set up at the indicated ratios
with the labeled targets (10
 
4 
 
targets/well) at 37
 
8
 
C, and superna-
tants were collected after 4 h and radioactivity was detected by 
 
g 
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counting. Means and SEs of duplicate cultures are shown. The
percentage of cytotoxicity was calculated using the formula: 100 
 
3
 
(cpm experimental 
 
2 
 
cpm spontaneous) / (cpm total 
 
2 
 
cpm
spontaneous). Spontaneous release was typically 10–15% of the
maximum release.
 
RNase Protection Assay.
 
Total RNA from 10
 
7
 
 Tc1 and Tc2
effectors cells was prepared on day 4 after in vitro primary culture
before (t
 
0
 
) and after restimulation with plate-bound anti-CD3
mAb (2C11; 10 
 
m
 
g/ml) for the indicated times using TRIzol
Reagent (GIBCO BRL). mRNA levels were then determined
using the RNase protection assay kit “RiboQuant Multipurpose
Ribonuclease Protection Assay (RPA) System” (PharMingen)
and the following probe sets (all from PharMingen): mCK-1,
mCK-3 for cytokine mRNA and mCR-5, and mCR-6 for
chemokine-R mRNA. The dried gel was placed on film (East-
man Kodak Co.) in a cassette with an intensifying screen and de-
veloped at 
 
2
 
70
 
8
 
C. Bands were detected using the densitometric
feature of the Quantity One software (Bio-Rad Labs.) and nor-
malized against the housekeeping gene L32.
 
Madine Derby Canine Kidney Virus Plaque Assay.
 
Viral titers of
infected lungs were determined using the Madine Derby canine
kidney (MDCK) cell plaque assay modified from the methods de-
scribed by Lukacher et al. (4). In brief, lungs were snap-frozen in
liquid nitrogen at the indicated time points after influenza virus
infection and stored at -70
 
8
 
C until ready for titration. MDCK
monolayers were grown in DMEM supplemented with 10%
FCS, 0.01 mM MEM amino acid solution (GIBCO BLR), 1 mM
sodium pyruvate (GIBCO BLR), and PSG (200 IU/ml penicil-
lin, 200 
 
m
 
g/ml streptomycin, and 4 mM glutamine). 10-fold
dilutions of the lung homogenates were prepared in DMEM sup-
plemented with 0.2% BSA, 2 mg/ml NaHCO
 
3
 
, 2 mM Hepes,
and PSG. 100 
 
m
 
l of each dilution was added to confluent mono-
layers of MDCK cells in 12-well plates in duplicates for 1 h at
37
 
8
 
C, 7% CO
 
2
 
. Each well received 1 ml of an agar overlay me-
dium containing DMEM, 0.2% BSA, 2 mg/ml NaHCO
 
3
 
, 2 mM
Hepes, PSG, 0.5% agar (Sigma Chemical Co.), 0.01% DEAE
Dextran, and 0.5 
 
m
 
g/ml trypsin. After a 3-day incubation at
37
 
8
 
C, cells were fixed for at least 20 min with 0.5 ml Carnoy’s
fixative (3:1, methanol/glacial acetic acid). The agar overlay was
then removed and fixed monolayers were stained by adding a
1:10 dilution of 2% crystal violet prepared in 20% ethanol. The
results are presented as PFUs/ml
 
 5 
 
(mean number of plaques/0.1) 
 
3
 
(1/dilution factor).
 
Flow Cytometry.
 
The following mAbs were used for immuno-
fluorescent staining: Cy-chrome anti-CD8 (PharMingen), FITC
anti-CD62L (PharMingen, clone Mel-14), FITC anti-CD44
(PharMingen, clone IM7), FITC anti-Ly6C (PharMingen, clone
AL-21), and PE anti-CD90 (Thy 1.2, PharMingen). After stain-
ing with the appropriate mAbs, FACS
 
®
 
 analysis was carried out
on a FACScan
 
®
 
 by using the Cell Quest (Becton Dickinson) soft-
ware. All plots shown were gated on the PI-negative, live popu-
lation.
 
Lung Histology.
 
Lungs were infused with 1 ml O.C.T. me-
dium (VWR, Rochester, NY), and then were frozen in liquid
nitrogen and stored at 
 
2
 
70
 
8
 
C. 5-
 
m
 
m sections were cryostat cut
onto poly-
 
l
 
-lysine-coated (Sigma Chemical Co.) slides and fixed
in 
 
2
 
20
 
8
 
C acetone for 5 min. Endogenous peroxidases were
blocked in 0.3% hydrogen peroxide for 30 min. For further
blocking, the avidin/biotin blocking kit No. SP2001 (Vector
Labs.) was used and nonspecific binding to Fc receptors was
blocked with 2.4G2 mAb. Sections were stained with biotiny-
lated Thy 1.2 mAb (PharMingen) and the Vectastain Elite ABC
kit for peroxidase systems (Vector Labs.). The color reaction was
 
developed using the AEC substrate kit for horseradish peroxidase
systems (Vector Labs.). Sections were counterstained with hema-
toxylin (Vector Labs.).
 
Tissue Sampling.
 
For bronchoalveolar lavage, mice were
anesthetized and bled out from the axilla. The trachea was then
exposed and a disposable plastic cannula with a syringe attached
was then inserted through an incision immediately posterior to
the larynx. The respiratory tract was washed out in a reproduc-
ible manner using four separate 1-ml aliquots of PBS containing
3 mM EDTA. Subsequently, the lavaged cells were centrifuged
and live cell counts were performed by excluding trypan blue–
positive dead cells.
For lung digest, lungs of killed animals were flushed in situ
with 20 ml PBS via cannulation of the heart to remove the intra-
vascular blood pool. Minced lung tissue was then incubated on a
rocker with collagenase (1 mg/ml; Sigma Chemical Co.) and
DNase (50 U/ml; Sigma Chemical Co.) for 1 h and passed
through a stainless steel mesh. After centrifugation live cell counts
were performed by excluding trypan blue–positive dead cells.
 
Results
 
Cytokine Production and Cytokine mRNA Expression of In
Vitro–generated HA Peptide–specific Tc1 and Tc2 CD8 T Cell
Effectors.
 
Naive CD8 T cells were isolated from the clone
4 TCR transgenic mice (23) carrying the V
 
a
 
10/V
 
b
 
8.2
TCR specific for a hydrophobic peptide sequence (amino
acids 518–528, IYSTVASSL) from the transmembrane re-
gion of the HA2 molecule from influenza virus. After en-
richment typically 
 
.
 
95% of the CD8 cells were naive as as-
sessed by low CD44 expression as previously described
(10). CD8 T cell effectors producing type 1 and type 2 cy-
tokines were generated by culturing transgenic CD8 T cells
with HA peptide–loaded APCs in the presence of IL-2, IL-12,
and anti–IL-4 mAb, or IL-2, IL-4, and anti–IFN-
 
g
 
 mAb,
respectively, for 4 d. A representative cytokine profile of
the in vitro
 
–
 
generated CD8 effector populations assessed
by specific ELISA is shown in Table I. Tc1 effectors pro-
duced IFN-
 
g
 
 but no detectable IL-4 or IL-5 upon stimula-
tion with mitomycin-treated HA peptide–loaded P815
 
Table I.
 
Cytokine Production of Tc1 and Tc2 Effectors before 
Adoptive Transfer Measured by Specific ELISAs
 
IFN-
 
g
 
IL-4 IL-5
 
ng/ml ng/ml U/ml
 
Tc1 effectors 1,020 
 
6
 
 29 – –
Tc2 effectors 95 
 
6
 
 8 7.6 
 
6
 
 0.09 7,963 
 
6
 
 364
Tc1 and Tc2 effectors were generated as described in Materials and
Methods. On day 4 of in vitro primary stimulation, Tc1 and Tc2 effec-
tors were washed and restimulated with P815 cells used as APCs loaded
with the HA peptide (11 
 
m
 
M). Supernatants were collected after 24 h
and the amounts of IFN-
 
g
 
, IL-4, and IL-5 were measured by specific
ELISA. Means 
 
6
 
 SE of triplicate wells of 1 representative experiment
out of 10 are shown. No cytokine production was detected when Tc1
and Tc2 effectors were restimulated in the absence of the HA peptide
(data not shown).426 Migration and Localization of Type 1 and Type 2 CD8 T Cell Effectors
cells used as APCs (Table I). No cytokine production was
observed with APCs in the absence of HA peptide (data
not shown), indicating that the response was highly anti-
gen-specific. In contrast, Tc2 effectors produced IL-4, IL-5,
and typically 10-fold lower amounts of IFN-g as compared
with Tc1 effector cells. Additional information about cy-
tokine mRNA expression within CD8 T cell subsets was
obtained in RNase protection assays (Fig. 1, A and B) and
mRNA was harvested on day 4 of the primary in vitro cul-
ture t0 and at the indicated time points after restimulation
with plate-bound anti-CD3 mAb. The predominant cy-
tokines expressed in Tc1 effectors were IFN-g (Fig. 1 A),
TNF-b, lymphotoxin-b (LT-b), and TNF-a (Fig. 1 B).
Tc1 effectors also expressed low levels of IL-10. No expres-
sion of mRNA specific for IL-4, IL-5, or IL-13 was detected
with Tc1 effectors. In contrast, high levels of mRNA for
IL-13 and IL-10 were found to be expressed with Tc2 effec-
tors even t0. Upon restimulation with plate-bound anti-CD3
mAb, Tc2 effectors expressed mRNA for IL-4, IL-5, and
strongly upregulated mRNA for IL-13. With Tc2 effectors a
low level of IFN-g mRNA (27-fold less as compared with
the expression with Tc1 effectors at t0 assessed by densitome-
try) was slightly upregulated upon restimulation (Fig. 1 A),
whereas mRNA specific for TNF-b and LT-b was down-
regulated upon restimulation (Fig. 1 B).
Both Tc1 and Tc2 Effectors Are Equally Cytolytic before
Adoptive Transfer. We next determined the cytolytic ac-
tivity of Tc1 and Tc2 effectors before adoptive transfer
(Fig. 2). Both Tc1 and Tc2 effectors were highly cytolytic,
killing HA peptide–loaded targets but not –unloaded tar-
gets. When targets were loaded with titrated doses of the
HA peptide (from 1.1 to 1.1 3 1026 mM), a similar dose
response to peptide was seen with Tc1 and Tc2 effectors.
The Tc2 effectors were usually slightly more cytotoxic
than the Tc1 population, ruling out that the observed cyto-
toxicity of the effectors generated under type 2–inducing
conditions was merely due to the small number of the con-
taminating Tc1 IFN-g–producing population (Table I).
On day 4 of stimulation, both Tc1 and Tc2 populations
were highly activated blast-sized cells with a high forward
scatter, expressing high levels of activation markers as pre-
viously described (10), and all cells expressed CD8, Thy
1.2, and the transgene Vb8. No persisting mitomycin-
treated APCs were detected on day 4 by FACS® analysis
(data not shown).
Adoptive Transfer of Tc1 Effectors But Not Tc2 Effectors Re-
duces the Pulmonary Virus Titer on Day 4 after Influenza Virus
Infection. The CD8 T cell–mediated recovery of hosts le-
thally infected with influenza virus was shown to be associ-
ated with a reduction in pulmonary virus titer (4). Thus,
we tested the ability of HA peptide–specific Tc1 and Tc2
effectors to reduce the pulmonary virus titer during infec-
tion with influenza virus upon adoptive transfer. On day 4
of primary culture 107 HA peptide–specific Tc1 or Tc2 ef-
fectors from the clone 4 TCR transgenic mice were adop-
tively transferred into BALB/c hosts that were infected
with 10 LD50 whole influenza virus (A/PR/8/34) z1 h
before the cell transfer as previously described (4). Infected
hosts, which had not received CD8 effector cells, were
used as controls. Influenza-infected recipients of Tc1 or
Tc2 effectors or lethally infected mice that had not re-
ceived cells were killed on day 4 after infection, and infec-
tious virus particles in mouse lung extracts were titered by
plaque formation on monolayers on MDCK fibroblast cells
(Table II). Adoptive transfer of Tc1 effectors resulted in a
1,000-fold reduction of pulmonary virus titer on day 4 after
infection and cell transfer as compared with infected mice,
which had not been injected with HA peptide–specific ef-
Figure 1. Cytokine mRNA expres-
sion within CD8 T cell subsets. On day 4
after in vitro culture RNA from 107 Tc1
and Tc2 effectors was prepared (t0) as
described in Materials and Methods.
Subsequently, 107 Tc1 or Tc2 effectors
were restimulated with plate-bound anti-CD3 mAb (10 mg/ml) and
RNA was prepared at the indicated time points. The RiboquantTM
Multi-Probe protection assay mCK-1 (A) or mCK-3 (B) was used to de-
tect cytokine mRNA. The results shown are representative for two inde-
pendently performed experiments.
Figure 2. CTL activity of Tc1
and Tc2 effectors. The cytolytic
activity of 4 d Tc1 (j) and Tc2
effectors (e) was assayed in a 4-h
51Cr-release assay. P815 cells (104
cells/well) pulsed with titrated
amounts of the HA peptide (1.1–
1.1 3 1026 mM, indicated in the
lefthand corners) were used as
targets. The results are represen-
tative for three independently
performed experiments.427 Cerwenka et al.
fectors. At this time point, only a slight reduction (fivefold)
of virus titer was observed with recipients of Tc2 effectors.
When kinetics experiments were carried out longer, we
found that recipients of Tc1 effectors had almost totally
cleared the pulmonary virus titer by day 5 after infection,
when the pulmonary viral load of recipients of Tc2 effec-
tors and animals that had not received CD8 T cells was still
high (data not shown). On day 7, recipients of Tc1 effec-
tors had completely cleared the virus from their lungs;
however, several animals from the other groups were al-
ready dead at this time point (data not shown).
Tc2 Effectors Enter the Lung with Delayed Kinetics. The
results thus far indicate that Tc1 CD8 T cells, but not Tc2
CD8 T cells, reduced the pulmonary viral titer on day 4 af-
ter influenza virus infection. Because CD8 T cell homing
to the lung is critical for the contact-dependent lysis of the
virus-infected airway epithelial cells and subsequently for
virus clearance, we determined the total cell counts of Tc1
and Tc2 effector cells from the lung lavage during pulmo-
nary influenza virus infection. We adoptively transferred
107 Tc1 or Tc2 effectors (donor cells were Thy 1.2–posi-
tive) into Thy 1.1 BALB/c hosts and assessed percentages
of donor cells by CD8/Thy 1.2 staining and subsequent
FACS® analysis on days 1, 3, 5, and 7 from the lung lavage
(Fig. 3). On day 3 after influenza infection and cell transfer,
70% of cells recovered from the lavage of recipients of Tc1
effectors were donor cells staining positive for CD8 and
Thy 1.2, whereas only 10% of the cells recovered from re-
cipients of Tc2 effectors were of donor phenotype. To as-
sess absolute donor cell numbers, total cell counts from the
lung lavage (Fig. 4 a), tracheal bronchial lymph node
(TBLN) (Fig. 4 b), and spleen (Fig. 4 c) were performed
and combined with the percentages of donor cells as deter-
mined by FACS® to calculate the total donor cells. Very
few cells were seen at any of the sites on day 1. Since the
adoptively transferred cells were injected at 4 PM on day
zero and the day 1 mice were killed at 7 AM, the first time
point is 17 rather than 24 h and the transferred cells were
presumably still in the circulation. On day 3 after influenza
infection and cell transfer, sixfold more Tc1 effectors were
found in the lung lavage as compared with Tc2 effectors
and threefold more Tc1 effectors as compared with Tc2 ef-
fectors were found in the spleen. Similar numbers of Tc1
and Tc2 effectors were found in the TBLN. However, on
day 7 comparable numbers of Tc1 and Tc2 effectors were
found in the lung lavage, spleen, and TBLN. Together,
these data indicate that Tc2 effectors enter the lung tissue
with delayed kinetics.
Tc1 and Tc2 Effectors Localize to Different Sites in the Lung
Tissue during Influenza Infection. The next experiments
were designed to visualize the localization of the Tc1 and
Tc2 population in the lung tissue by immunohistochemis-
try. On day 5 after infection with influenza virus and cell
transfer, frozen sections of recipient lungs were stained
Table II. Adoptive Transfer of Tc1 Effectors Results in Reduction 
of the Pulmonary Virus Titer (Day 4 after Infection)
Transfer of Pulmonary virus titer
PFU/ml
Tc1 effectors 4 6 1 3 102
Tc2 effectors 8 6 3 3 104
no cells 4 6 1 3 105
107 Tc1 and Tc2 effectors from the HA TCR transgenic mice were
adoptively transferred into hosts infected with 10 LD50 influenza virus
and the pulmonary virus titer was assessed on day 4 after infection and
cell transfer using the MDCK virus plaque assay as described in Materi-
als and Methods. Three individual mice per group were analyzed. The
data shown represent the mean 6 SE and are representative of three in-
dependently performed experiments.
Figure 3. Kinetics of migra-
tion of Tc1 and Tc2 effectors to
the lung. 107 Tc1 and Tc2 effec-
tors expressing Thy 1.2 were
adoptively transferred into influ-
enza infected Thy 1.1 BALB/c
hosts and cells from lung lavages
of recipients of Tc1 (left panels)
or Tc2 (right panels) effectors
were stained with Thy 1.2 PE
and CD8 FITC in order to iden-
tify cells of donor origin on days
1, 3, 5, and 7. Dot-plots were
gated on PI-negative live cells.
The migration kinetics into the
lung of one representative animal
out of three is shown.
Figure 4. Absolute donor cell
numbers recovered from lung la-
vage, spleen, and TBLN on days
1, 3, 5, and 7 after influenza vi-
rus infection and  cell  transfer.
107 Tc1 and Tc2 effectors ex-
pressing Thy 1.2 were adoptively
transferred into influenza-infected
Thy 1.1 BALB/c hosts as de-
scribed in Fig. 3. To assess abso-
lute donor cell numbers in the
different organs, total cell counts
from the isolated organs were
performed and were multiplied
by the percentages of donor cells
determined by FACS® as shown
in Fig. 3. Here, three animals per
group were analyzed and the av-
erage donor cell numbers 6 SE
isolated from lung lavage (a),
TBLN (b), and spleen (c) are
shown. It should be noted that
the adoptively transferred cells
were injected at 4 PM on day 0
and the day 1 mice were killed at
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with a Thy 1.2 mAb to identify donor CD8 T cells (Fig.
5). Specific staining for Thy 1.2 was found in both groups,
but distinct localization of Tc1 versus Tc2 effectors was ob-
served. Tc1 effectors were found near the basement mem-
brane of the airway (Fig. 5, A and C), whereas Tc2 effec-
tors localized predominantly within large clusters of cellular
infiltrates distant from the airway epithelium and also scat-
tered throughout the alveolar air spaces and septa (Fig. 5, B
and D). Most of the cells within the cell clusters of the al-
veolar parenchyma stained positive with the mAb RB-6,
which specifically stains neutrophils and eosinophils, and
colocalized in the clusters with Tc2 effectors (Cerwenka,
A., manuscript in preparation).
Tc1 and Tc2 Effectors Express Distinct Patterns of Chemokine
Receptors. Chemokines, as well as adhesion molecules,
have been shown to be a key component of the leukocyte
recruitment process, and human polarized CD4 T cell
clones expressing distinct patterns of chemokine receptors
were shown to differentially migrate in response to differ-
ent chemokines in vitro (21, 22). We therefore examined
whether Tc1 and Tc2 CD8 T cell effectors differed in the
expression of chemokine receptors by RNase protection
assay (Fig. 6, A and B). RNA from 4 d in vitro generated
Tc1 and Tc2 effectors was extracted t0 and after restimula-
tion for 5 and 24 h with plate-bound anti-CD3 mAb. Ex-
pression of CCR1 was selectively found with Tc2 effectors
upon stimulation. Tc1 effectors expressed higher levels of
CCR5 (7.8-fold difference by densitometry) and CCR2
(8.1-fold difference) as compared with Tc2 effectors t0. At
24 h after restimulation, similar levels of CCR5 and CCR2
were found in the Tc1 and the Tc2 subsets. The chemo-
kine receptor CCR4 was expressed in Tc2 effectors at
higher levels than in Tc1 effectors (threefold difference)
and this expression remained high in Tc2 effectors upon
restimulation. However, in Tc1 effectors, expression of
CCR4 was undetectable upon restimulation at 24 h. Both
Tc1 and Tc2 effectors expressed CXCR4 and downregu-
lated expression of this chemokine receptor upon restimu-
lation. CXCR2 selectively was expressed within the Tc1
subset and was downregulated upon activation (Fig. 6 B).
Phenotype of Tc1 and Tc2 Effector Donor Cells on Day 5 af-
ter Infection and Cell Transfer.  Next, we tested whether
Tc1 and Tc2 effectors differed in the expression of surface
markers when reisolated from different sites during influ-
enza virus infection. Representative staining profiles of Tc1
and Tc2 effectors isolated from TBLN and lung tissue on
day 5 is shown in Fig. 7. Histograms are gated on live Thy
1.2–positive cells and similar results were obtained when
donor cells were phenotyped on days 3 and 7 after infec-
tion. We have previously described that before adoptive
transfer both Tc1 and Tc2 effectors express high levels of
the activation markers CD44 and CD25, and a low level of
CD62L on day 4 after in vitro primary stimulation (10).
On day 5 after adoptive transfer into influenza-infected
hosts, both Tc1 and Tc2 donor cells were CD44high and
CD62Llow regardless of whether they were isolated from
the lymph node or lung lavage. Expression of CD25 was
low in both Tc1 and Tc2 effectors isolated on day 5 in vivo
Figure 5. Immunohistochemistry of lungs of recipients of Tc1 and Tc2
effector cells. 107 Tc1 (A and C) and Tc2 effectors (B and D) expressing
Thy 1.2 were adoptively transferred into influenza-infected Thy 1.1
BALB/c hosts. On day 5 after infection and cell transfer, lungs were re-
moved and frozen sections were prepared as described in Materials and
Methods. Sections were stained with a biotinylated Thy 1.2 mAb or the
respective biotinylated isotype control, and the color reaction was devel-
oped using a red substrate. The staining for Thy 1.2 (donor cells) was
highly specific, because no red stain was detected when slides were incu-
bated with the respective isotype control (data not shown). Original mag-
nification: A and B, 3100; C and D, 3200. The results are representative
of four independently performed experiments.
Figure 6. Chemokine receptor mRNA expression within CD8 T cell
subsets. On day 4 after in vitro stimulation RNA from 107 Tc1 and Tc2
effectors was prepared (t0) as described in Materials and Methods before
adoptive transfers. 107 Tc1 and Tc2 effectors were restimulated with
plate-bound anti-CD3 mAb (10 mg/ml), and RNA was prepared at the
indicated time points. The RiboQuantTM Multi-Probe protection assay
mCR-5 (A) or mCR-6 (B) was used to detect chemokine receptor
mRNA. The results shown are representative for three independently
performed experiments.429 Cerwenka et al.
(data not shown). Before adoptive transfer on day 4 of pri-
mary in vitro stimulation, both Tc1 and Tc2 effectors were
Ly6Clow (10). However, on day 5 after adoptive transfer,
Tc1 and Tc2 effectors differed profoundly with regard to
the expression of the surface marker Ly6C. On day 5 after
infection and cell transfer Tc1 effectors had upregulated
high levels of Ly6C in all tissues sampled, whereas expres-
sion of Ly6C on Tc2 effectors was low in the lymph node
and lung lavage. The absence of Ly6C might be a distinct
feature of the Tc2 subset at early time points during influ-
enza infection in vivo.
Tc1 and Tc2 Effectors Retain Their Cytokine Polarization
and Cytolytic Activity In Vivo. We have shown previously
that the cytokine phenotype of Tc1 and Tc2 effectors is
stable and that in the apparent absence of antigen stimula-
tion Tc1 and Tc2 effectors gave rise to Tc1 and Tc2 mem-
ory cells, respectively (10). However, in this study we
transferred Tc1 and Tc2 effectors into influenza-infected
hosts. A virus infection creates a microenvironment where
high levels of a variety of cytokines are produced, which
might then influence the polarization of the transferred do-
nor CD8 effectors studied. In addition, it was important to
establish whether Tc1 and Tc2 effectors retained their po-
larization pattern after the transfer in vivo, particularly be-
cause our Tc2 effectors always produced a low level of
IFN-g (Table I). To this end we isolated CD8 T cells from
lung digests from influenza-infected hosts (BALB/c Thy
1.1), which were adoptively transferred with either Tc1 or
Tc2 effectors expressing Thy 1.2 on day 4 of infection and
cell transfer. CD8 T cells were enriched and similar cell
numbers of donor cells were restimulated with HA pep-
tide–loaded P815 cells (Fig. 8 a). When cytokine produc-
tion of the whole CD8 T cell population was determined,
CD8 T cells of hosts that had received Tc1 effectors pro-
duced high amounts of IFN-g and no IL-4 or IL-5. CD8 T
cells from hosts that had received Tc2 effectors produced
IL-4 and IL-5, but no production of IFN-g could be ob-
served. When we depleted donor cells from the cell prepa-
ration by depleting Thy 1.2–positive cells with mAb and
complement before restimulation in vitro, no cytokine
production was observed, indicating that at this time point
all the polarized cytokine production was due to the pres-
ence of the donor cell population (data not shown). Similar
patterns of cytokines were observed when donor cells were
isolated from the TBLN and the spleen (data not shown).
No cytokine production was detected by ELISA when cul-
tures were restimulated with APCs in the absence of the
HA peptide (data not shown). When the cytolytic activity
was assessed from donor cells isolated from the lung tissue
on day 4 after infection, both Tc1 and Tc2 effectors were
equally cytolytic on a per cell basis assayed on HA peptide–
loaded targets (Fig. 8 b). In this context it is important to
note that only half the cell number of Tc2 effectors as com-
pared with Tc1 effectors was found in the lung at this time
point (day 4) and thus, if the figure were not corrected for
donor cell input number, only half the cytolytic activity of
the lung digest recipients of the Tc1 effectors would be
found in the lung digest compared with recipients of Tc2 ef-
fectors. All the cytolytic activity found in the lung tissue at
this time point was due to donor cells because no killing of
HA peptide–loaded target cells was found when the effectors
Figure 7. Phenotype of Tc1
and Tc2 donor cells upon re-iso-
lation from infected hosts. 107
Tc1 and Tc2 effectors expressing
Thy 1.2 were adoptively trans-
ferred into influenza-infected
Thy 1.1 BALB/c hosts. On day 5
after infection and cell transfer,
TBLN (a) or lung lavages (b) of
recipients of Tc1 or Tc2 effectors
were double stained with FITC-
conjugated mAbs directed against
CD44, Ly6C, and CD62L, re-
spectively and with PE-conju-
gated Thy 1.2 mAb analyzed on
a FACScan®. Histograms were
gated on Thy 1.2–positive and
PI-negative live cells. Data are
representative of three similar ex-
periments performed.
Figure 8. (a) Tc1 and Tc2 ef-
fectors retain their polarization
profile during influenza infection
in vivo. Tc1 and Tc2 effectors
(107) were adoptively transferred
into influenza-infected hosts. On
day 4 after infection and cell
transfer, CD8 T cells were en-
riched from the lung digest and
similar numbers of Tc1 and Tc2
donor cells (Thy 1.2–positive
cells) were restimulated with
P815 loaded with the HA pep-
tide (11 mM). Supernatants were
collected after 24 h and cyto-
kines were measured by specific
ELISAs. No cytokines were de-
tected when Tc1 and Tc2 effec-
tors were restimulated in the ab-
sence of the HA peptide (data
not shown). No cytokines were
detected when the cell cultures
were depleted of Thy 1.2 (donor
cells)–positive cells, indicating
that the observed cytokine pro-
duction was due to the adop-
tively transferred Thy 1.2 donor
cell population (data not shown).
(b) CTL activity of Tc1 and Tc2
effectors upon reisolation from
infected lung tissue. 107 Tc1 (j)
and Tc2 effectors (h) were
adoptively transferred into influ-
enza-infected hosts. On day 4 af-
ter infection and cell transfer,
CD8 T cells were enriched from
the lung digest and similar numbers of Tc1 and Tc2 donor cells (Thy 1.2–
positive cells) were assayed in a 4-h 51Cr-release assay using P815 cells
(104 cells/well) pulsed with the HA peptide (11 mM) as targets. Only little
CTL activity was detected, and the effectors were depleted of Thy 1.2
(donor cells)–positive cells (r) in vitro before the CTL assay, indicating
that the observed CTL activity was indeed due to the adoptively trans-
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were depleted of donor (Thy 1.2–positive) cells before the
cytolytic assays were set up.
Survival of Lethally Influenza Virus–infected Recipients of Tc1
and Tc2 Effectors Generated from the Clone 4 TCR Transgenic
Mice on the Wild-type or IFN-g2/2 Background. Finally, we
tested whether Tc1 and Tc2 effectors differentially pro-
moted host recovery from lethal infection with influenza
virus (Fig. 9 a). A high dose (107 effector cells) and a low
dose (106 effector cells), respectively, of Tc1 or Tc2 effec-
tors generated from the clone 4 TCR transgenic mice on
the wild-type background were adoptively transferred into
syngeneic sex- and age-matched recipients that had been
infected with 10 LD50 influenza virus intranasally 1 h be-
fore the adoptive transfer of effectors (Fig. 9 a). Survival
was monitored until day 21 after infection. All animals that
had not received HA peptide–specific effector CD8 T cells
died between days 6 and 10, indicating that a lethal dose of
influenza virus was administered. When a high cell number
of Tc1 or Tc2 effector cells (107 cells) was adoptively trans-
ferred, all recipients of Tc1 effectors were protected and
survived, whereas only 60% of Tc2 effector recipients sur-
vived. When lung function studies of these mice were per-
formed, recipients of Tc2 effectors were found to be sicker
at all time points as compared with the recipients of Tc1 ef-
fectors with a lower level of pO2 in their blood (Cerwenka,
A., manuscript in preparation). At 106 Tc1 or Tc2 effector
cells transferred, all hosts died except one recipient mouse
of Tc1 effectors.
To investigate the role of IFN-g in the protective value
of Tc1 and Tc2 populations against pulmonary influenza
virus infection, we performed parallel experiments with ef-
fectors generated from the clone 4 TCR transgenic mice
crossed to the IFN-g2/2 background on BALB/c (Fig. 9
b). When Tc1 and Tc2 effectors from these mice were
characterized with regard to cytokine production, we
found that the levels of IL-4 and IL-5 in the Tc2 effectors
were comparable to the wild-type, and neither Tc1 and
Tc2 effectors produced any detectable IFN-g (Fig. 9 b).
Tc1 effectors from the wild-type and IFN-g2/2 back-
grounds were found to be equally cytolytic before transfer
(data not shown). Adoptive transfer of Tc1 and Tc2 effec-
tors from clone 4 3 IFN-g2/2 mice into influenza-infected
mice was performed and survival was monitored. Fig. 9 b
shows Tc1 effectors from the clone 4 3 IFN-g2/2 mice at
107 cells transferred were still protective, indicating that
IFN-g production was not required. However, all recipi-
ents of Tc2 effectors generated from the clone 4 3 IFN-
g2/2 mice died.
Discussion
In this study we investigated the in vivo function and
distribution of HA peptide–specific Tc1 and Tc2 CD8 T
cell effectors during pulmonary influenza virus infection.
We show that Tc1 effectors, but not Tc2 effectors, very ef-
ficiently reduced the pulmonary virus titer (Table II), de-
spite the fact that both populations were highly cytolytic
before (Fig. 2) and after (Fig. 8 b) adoptive transfer. Tc1 ef-
fectors were found in high numbers in the lung lavage on
day 3 after infection and cell transfer. Tc2 effectors, how-
ever, entered or accumulated in the lung tissue with de-
layed kinetics (Figs. 3 and 4). In addition, Tc1 and Tc2 ef-
fectors localized to distinct sites within the infected lung
tissue (Fig. 5): Tc1 effectors predominately localized near
the virus-infected airway epithelium, whereas Tc2 effectors
were found more widely scattered in the alveolar paren-
chyma distant from the infected airway epithelium. Fur-
thermore, we demonstrate that Tc1 and Tc2 effectors
differed profoundly in their expression of chemokine re-
ceptors, which might account for their different migratory
behavior (Fig. 6, A and B).
In general, the effectiveness of a CD8 T cell population
to protect a previously unexposed animal against a confined
replicating organism is determined by its ability to provide
cell-mediated immunity before uncontrolled viral growth
has taken over (1, 24). Complex mechanisms could be in-
volved in the observed differential protection of virus-
infected hosts after adoptive transfer of Tc1 and Tc2 effec-
tor populations.
Figure 9. Recipient survival after adoptive transfer of Tc1 and Tc2 ef-
fector cells into lethally influenza-infected hosts. Tc1 (dashed line) and
Tc2 effectors (gray line) generated from the clone 4 TCR transgenic mice
on the wild-type (a) or on the IFN-g2/2 background (b) were prepared as
described in Materials and Methods. Cytokine production of the effector
populations before adoptive transfer is indicated. On day 4 of primary
stimulation, cells were washed and 107 (center panel) or 106 (bottom
panel) effector cells were adoptively transferred into sex- and age-
matched BALB/c recipients, which were infected intranasally with 10
LD50 of the influenza virus PR8, approximately 1 h before the cell trans-
fer. As a control no cells were injected into influenza-infected hosts (thin
line) and all recipient animals died. The percentage of survival of five ani-
mals per group is presented for the time points indicated. Survival was
monitored for 21 days. Data presented are representative for 4 (a) or 2 (b)
independently performed experiments.431 Cerwenka et al.
Protection could be due to the adoptive transfer of a
high frequency of virus-specific CD8 T cells and might not
directly be the result of the effector potential of the trans-
ferred T cell population. In this context, we observed that
the adoptive transfer of high numbers of naive unprimed
HA peptide–specific CD8 T cells did not result in protec-
tion but rather in accelerated death of the recipients (Cer-
wenka, A., manuscript in preparation). Thus, the protec-
tion observed with Tc1, and to a lesser extent with Tc2
effectors, was not simply due to the higher frequencies of
influenza virus-specific cells but rather the result of the ef-
fector quality of the transferred CD8 T cell population.
We defined the Tc1 and Tc2 effector cell populations
with regard to the cytokines produced in vitro and in vivo
(Figs. 1 and 8 a). On day 4 after primary in vitro stimula-
tion, the Tc1 effectors made high amounts of IFN-g and
also expressed a high level of mRNA for TNF-b, LT-b,
and TNF-a. In contrast, Tc2 effectors made IL-4, IL-5,
and little IFN-g, and expressed high levels of mRNA spe-
cific for IL-10 and IL-13. Tc2 effectors expressed lower
levels of RNA specific for TNF-b, LT-b, and TNF-a,
which almost disappeared upon restimulation. Our data
with polarized CD8 T cells showing selective expression of
LT-b within the Tc1 subset is in concordance with data
recently published for CD4 subsets, suggesting that surface
LT-a/b is a surface marker for the Th1 subset (25). In our
previous study, we showed that upon adoptive transfer into
athymic, bone marrow–reconstituted animals (10) or nor-
mal recipients (data not shown), Tc1 or Tc2 effectors gave
rise to Tc1 or Tc2 memory cells, respectively. This indi-
cates that the polarized cytokine phenotype is a stable fea-
ture of CD8 subsets. In this study, we investigated whether
Tc1 and Tc2 populations retained their polarized cytokine
profile in virus-infected hosts where presumably high
amounts of a variety of cytokines were produced. We also
found that in this situation the cytokine-producing pheno-
type was remarkably stable (Fig. 8 a). Several studies
showed that during pulmonary influenza infection a variety
of cytokines were expressed within both the CD4 and the
CD8 subsets, which could not be clearly categorized into
the type 1 or the type 2 pattern (17). This study dissects the
role of CD8 T cells as a source of polarized cytokines. Cy-
tokines and soluble factors produced by Tc1 and Tc2 effec-
tors might not only be involved in host protection but
might also mediate inflammation in the lung tissue and thus
influence the severity of lung immunopathology.
IFN-g, predominantly produced within the Tc1 subset,
has been shown to upregulate MHC class I expression on
antigen expressing cells (26), and thus might enhance the
expression of viral antigens on lung epithelium cells and
thereby accelerate viral clearance. To investigate the role
and requirement of IFN-g in our model, we tested the
protective value of Tc1 and Tc2 effectors generated from
the clone 4 TCR transgenic mice crossed to the IFN-g2/2
background (Fig. 9, a and b). All recipients of Tc1 effec-
tors, regardless whether they were on the wild-type or on
the IFN-g2/2 background, were protected. Pulmonary vi-
rus titer in lungs of recipients of Tc1 effectors from either
the wild-type and IFN-g2/2 background on day 4 after in-
fection were not significantly different (data not shown).
This suggests a minor role of IFN-g in our experimental
model. Our finding is in concordance with the observation
that mice lacking IFN-g successfully cleared pulmonary in-
fluenza virus infection (27). We speculate that the Tc1 ef-
fectors were more effective than the Tc2 effectors in viral
clearance because they arrived at the site of infection earlier
in high cell numbers, halting the spread of virus, and
homed more efficiently to the infected airway epithelium.
The type 2 cytokines IL-4 and IL-5 have been shown to
be mediators of severe lung inflammation in several disease
models, including viral (28) and allergy (29) models. Thus
far, the in vivo effects of type 2 cytokines have been gener-
ally studied with regard to CD4 T cells. Thus, the signifi-
cance of type 2 cytokine production within the CD8 pop-
ulations has not previously been defined. Adoptive transfer
of influenza-specific CD4 T cell clones into lethally in-
fected hosts resulted in influenza virus clearance when an
influenza-specific Th1 clone was adoptively transferred but
not when a Th2 clone was transferred (28). This protection
was shown to depend on the presence of B cells (30).
Adoptive transfer of Th2 effectors caused a higher number
of eosinophils in the lung and it was speculated that the
lack of protection with the Th2 clone was due to the im-
munopathology caused by this subset (28). Indeed, we ob-
served infiltrates of inflammatory cells including eosinophils
in recipient lungs of Tc2 effectors (Fig. 5 and Cerwenka,
A., manuscript in preparation) and we are currently further
investigating the immunopathology mediated by type 2
CD8 T cells. As in the study by Graham et al. (28), we
transferred Tc1 and Tc2 effectors into normal hosts and it
will be interesting to determine whether the transferred
Tc1 and Tc2 populations will alter the humoral influenza-
specific response of the hosts.
Contact-dependent cytolytic activity appears to be the
key effector mechanism used by CD8 T cells during influ-
enza virus infection (5). By using bone-marrow chimeras,
Topham et al. (5) demonstrated that perforin-mediated cy-
totoxicity was the preferred mode, although fas-based cyto-
toxicity can apparently serve as an alternative mechanism.
When we tested the cytolytic activity of Tc1 and Tc2 sub-
sets before adoptive transfer, we found that both subsets
were cytolytic regardless of the concentration of the HA
peptide loaded onto specific targets (Fig. 2). Our previous
study showed that cytotoxicity was mainly perforin-medi-
ated with a small component of fas-mediated cytotoxicity
(11). It had been shown that chronic stimulation of IL-4–
producing CD8 T cells with PMA and ionomycin resulted
in a loss of cytotoxicity (31). It was thus important to estab-
lish whether the adoptively transferred Tc1 and Tc2 popu-
lations retained cytolytic activity on a per cell basis in vivo.
Indeed, both Tc1 and Tc2 effectors reisolated from the
lung tissue on day 4 after influenza infection and cell trans-
fer were equally cytolytic on a per cell basis, ruling out the
possibility that the in vivo microenvironment had caused a
loss of cytolytic activity within the Tc2 subset (Fig. 8 b).
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have not only to enter the site of infection, i.e., the lung,
but also have to migrate to the site of infection, i.e., the vi-
rus-infected epithelium within the tissue site. Thus, despite
the fact that both Tc1 and Tc2 effectors were equally cy-
tolytic before adoptive transfer and were still equally cy-
tolytic when reisolated from influenza-infected hosts on a
per cell basis, Tc2 effectors might be less effective in pro-
tecting influenza infected hosts because of their different
migration pattern in vivo. First, Tc2 effectors entered the
lung with delayed kinetics as compared with Tc1 effectors.
On day 3 after influenza infection and cell transfer sixfold
more Tc1 effectors as compared with Tc2 effectors were
recovered from the lung lavage (Fig. 4, a and b). Second,
Tc2 effectors that had entered the lung on day 5 did not
localize predominantly at the virus-infected airway epi-
thelium as did the more protective Tc1 effector cells,
but rather were found within cellular infiltrates scattered
throughout the alveolar air spaces and septa. When frozen
sections were stained with an antibody staining specifically
for H1N1 influenza virus on day 5 after infection, positive
virus staining was detected only within the airway epithe-
lium of recipients of Tc2 effectors, whereas almost all the
virus was gone from the recipient lungs of Tc1 effectors
(data not shown), which is consistent with the viral titers
assessed by viral plaque assays (Table II).
A key finding of our study was a differential accumula-
tion of Tc1 and Tc2 effector cells at the tissue site of a lo-
calized virus infection. The Tc1 cells appeared in the lung
early (Fig. 4) and were found preferentially adjacent to the
airway epithelium (Fig. 5), whereas the Tc2 appeared later
and congregated more within clusters of inflammatory cells
distant from the epithelium. The accumulation of an adop-
tively transferred cell population at a particular site in the
recipient is the sum of the rate of entry into the tissue and
the rate of cell division and cell death both before and after
entry into the site. We can only speculate on the relative
contributions of each to the present situation. With respect
to proliferation, we have shown elsewhere (10) that adop-
tively transferred Tc1 and Tc2 effectors were equally effec-
tive at generating populations of CD8 memory cells when
transferred into adult-thymectomized, bone marrow-
restored recipients, which persisted at a slowly declining
number for many weeks. Tc1 and Tc2 CD8 effector cells
labeled with CFSE tracker dye (our unpublished observa-
tions) both lose label rapidly on adoptive transfer into Thy1
congenic normal mice, indicating rapid cell division, and
there is no indication of any difference in the kinetics be-
tween the two populations. There are no significant num-
bers of cells at any of the sites we monitored at 17 h (lung
lavage, TBLN, or spleen, Fig. 4). The number of transferred
cells recovered in the spleen at day 3 was threefold smaller
for the Tc2 than the Tc1 population (Fig. 4), but the num-
bers present in the lymph node were similar.
With regards to cell death, we have shown (our unpub-
lished data) that both Tc1 and Tc2 effectors underwent
activation-induced cell death when reexposed to antigen
in vitro at a relatively slow rate and that there was no dif-
ference between the two populations. However, we do not
know how these in vitro data relate to cell death of effector
populations after the adoptive transfer into virus infected
animals and our attempts to assay for cell death immediately
ex vivo by annexin V staining remained technically unsatis-
fying (unpublished observation). Finally, with regard to dif-
ferential homing, we have no direct evidence other than
the observation that the two cell populations do accumu-
late at different locations (Fig. 5) in the lung and at different
rates (Fig. 4). However, we do find that there is a very
significant difference both in the expression of several
chemokine receptors on the two populations and in the
change in expression of these receptors upon restimulation
in vitro, as further discussed below.
The regulation of lymphocyte migration is complex and
might involve not only the expression of certain adhesion
molecules such as selectins and integrins (20) but also
chemokines and chemokine receptors. Little is known about
the factors controlling migration into the lung or within the
lung tissue. Differential expression of chemokine receptors
was recently found with human Th1 and Th2 CD4 T cell
clones (21, 22), but so far the question of expression of
chemokine receptors with CD8 Tc1 and Tc2 subsets has not
been addressed. Recent studies with human CD4 T cell
clones not only correlated the expression of the chemokine
RNA with receptor surface expression but also demonstrated
functional significance of the expression of the chemokine
receptors by migration assays. For example, macrophage in-
flammatory protein (MIP)-1b, a CCR5 agonist, or eotaxin,
a CCR3 agonist, were shown to have chemotactic activity
for Th1 and Th2 clones, respectively (22). Thus, it is likely
that the differential expression of chemokine receptors by
CD8 subsets is also of functional significance. Thus far, the
studies done with human CD4 T cell clones, which repre-
sent a population of chronically stimulated cells, only looked
at constitutive expression of chemokine receptors. In con-
trast, we were studying chemokine receptor expression by
transgenic CD8 T cells of known specificity and defined
stages of differentiation. Thus, we could monitor the expres-
sion of chemokine receptors during restimulation of primary
effectors. We found that some chemokine receptors were
lost upon re-stimulation (e.g., CXCR4 by Tc1 and Tc2)
whereas others (e.g., CCR1, CCR5, and CCR2 by Tc2)
were acquired at 24 h upon restimulation. The timing of
up- and downregulation of chemokine receptors by Tc1 and
Tc2 subsets during stimulation has to be tightly regulated to
ensure the proper migration along certain chemokine gradi-
ents. In this study we analyzed the mRNA expression of five
C-C chemokine receptors (CCR1-5) and two C-X-C
chemokine receptors (CXCR2 and 4) of in vitro–generated
Tc1 and Tc2 CD8 T cell effectors by RNase protection as-
say (Fig. 6). At t0, Tc1 effectors selectively expressed CCR5,
the receptor for the chemokines MIP-1a and MIP-1b. Sim-
ilar expression patterns were found with human Th1 and
Th2 clones (22). CCR2, binding the chemokines monocyte
chemoattractant protein (MCP)-1 and MCP-3, was found
to be selectively expressed within the Tc1 subset before re-
stimulation which has not yet been demonstrated with CD4
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that CCR4, binding to the thymus-and-activation–regulated
chemokine (TARC), and CCR3, binding to eotaxin, were
predominately expressed in the Th2 subset. These expression
patterns are similar to those found in Tc1 and Tc2 subsets
(Fig. 6, A and B). Studies with CD4 and our study with
CD8 T cells show that type 1 and type 2 CD4 and CD8 ef-
fectors express similar patterns of chemokine receptors,
respectively, and might follow a similar path of migration
along certain chemokine gradients. The precise role of che-
mokines and chemokine receptors in the migration patterns
we have observed have yet to be defined.
In the field of adoptive immunotherapy, the challenge is
to target an effective cell population to the right place to
fight a tumor or a virus infection. In general, the protective
value of a CD8 T cell population against disease might de-
pend on the “effectiveness” to migrate to the “right” place
at the right time and to there do the right thing. Our study,
suggesting that localization of CD8 effector cells might be
crucial for their protective value during influenza virus in-
fection, might help the design for therapeutic intervention
during disease involving lung inflammation.
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